Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$70.49M+241.64%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Simeon Kohl
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 1,200
- Beta
- 1.54
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -6.55
Financials
Revenue
$70.49M+241.6%Net Income
$-40.54MEBITDA
$-29.24MFree Cash Flow
$-4.88MEPS (diluted)
$-0.55Shares Outstanding (diluted)
73.96M+166.4%Operating Expenses
$33.31MCash & Debt
$103.44MReturn of Capital
$0.00Revenue by Segment (annual)
$208.28MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $311.14M | $-177.97M | $-2.55 |
| 2024 | $306.58M | $-69.50M | $-1.15 |
| 2023 | $295.94M | $-118.15M | $-2.09 |
| 2022 | $276.24M | $-137.40M | $-2.56 |
| 2021 | $241.93M | $-153.21M | $-3.23 |
| 2020 | $188.84M | $-115.02M | $-2.91 |
| 2019 | $154.94M | $-60.10M | $-3.21 |
| 2018 | $112.57M | $-61.98M | $-2.23 |
| 2017 | $73.08M | $-47.03M | $-1.69 |
Valuation
HCAThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·2d ago·Neutral
…ng Results and Host Conference Call on Thursday, November 5, 2026 SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, will release its third quarter 2026 operating results on Thursday, November 5, 2026, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day.
View source ↗ - Newsprnewswire.com·40d ago·Neutral
Health Catalyst Strengthens Its Board with the Appointment of Tami Reller Reller Joins Health Catalyst as it Enters Its Next Phase of Growth SALT LAKE CITY, Sept. 14, 2026 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst", NASDAQ: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that Tami Reller has been appointed to its board of directors (Board), effective October 1, 2026.
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
Health Catalyst Appoints Simeon Kohl as Chief Executive Officer and President SALT LAKE CITY, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that Simeon Kohl has been appointed Chief Executive Officer (CEO) and President and a member of the Company's Board of Directors, effective September 14, 2026.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Health Catalyst to Participate in Upcoming Investor Conference SALT LAKE CITY, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that members of senior management will participate in the 2026 Wells Fargo Healthcare Conference, taking place in Boston, on Wednesday, September 9, 2026 and Thursday, September 10, 2026.
View source ↗
Earnings
Mon, Nov 9(in 2 weeks)
Consensus estimate $-0.02 per share
Typical surprise +20.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.04 vs $0.03beat
- Mon, May 11$0.02 vs $0.01beat
- Thu, Mar 12$0.08 vs $0.09miss
- Mon, Nov 10$0.06 vs $0.05beat
- Thu, Aug 7$0.04 vs $0.03beat
- Wed, May 7$0.01 vs $0.01beat
Estimates and results for HCAT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HCAT officers and directors.
- Bought
- $105k
- Sold
- $427k
1 trade
8 trades
- Kohl Simeonbought
- Landry Benjaminsold
- Larson-green Juliesold
- Landry Benjaminsold
- Landry Benjaminsold
- Lesueur Danielsold
- Lesueur Danielsold
- Landry Benjaminsold
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HCAT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.